Chinese Japanese Germany Korea


Description References
Gemcitabine structure
Chemical Name:
Zefei;Gemcel;GemLip;LY-18011;Folfugem;NSC 613327;GeMcitabin;GeMictabine;Gamcitabine;GEMCITABINE
Molecular Formula:
Formula Weight:
MOL File:

Gemcitabine Properties

Melting point:
168,64 C
365 +425.36°; D +71.51°
CAS DataBase Reference
95058-81-4(CAS DataBase Reference)


Hazard Codes  Xn,Xi
Risk Statements  21-36/38-46-62-63
Safety Statements  25-26-36/37-53
HS Code  29349990
Hazardous Substances Data 95058-81-4(Hazardous Substances Data)
Toxicity LD10 i.v. in rats: 200 mg/m2 (Abbruzzese)

Gemcitabine price More Price(4)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Cayman Chemical 11690 Gemcitabine ≥98% 95058-81-4 10mg $40 2018-11-13 Buy
Cayman Chemical 11690 Gemcitabine ≥98% 95058-81-4 25mg $71 2018-11-13 Buy
Cayman Chemical 11690 Gemcitabine ≥98% 95058-81-4 50mg $135 2018-11-13 Buy
Cayman Chemical 11690 Gemcitabine ≥98% 95058-81-4 100mg $240 2018-11-13 Buy

Gemcitabine Chemical Properties,Uses,Production


Gemcitabine (2’,2’-difluorodeoxycytidine; dFdCyd) is a novel deoxycytidine analogue with both structural and metabolic similarities to cytarabine. It has a broad spectrum of antitumor activity in preclinical murine leukemia and solid tumor models. This drug requires intracellular phosphorylation that results in the accumulation of difluorodeoxycytidine triphosphate (dFdCTP). The dFdCTP competes with deoxycytidine triphosphate (dCTP) for incorporation into DNA, which in turn inhibits DNA synthesis and terminates DNA chain elongation. In addition, this drug reduces intracellular deoxynucleoside triphosphate pools, presumably through the inhibition of ribonucleotide reductase.
Gemcitabine is used alone or with other treatments/medications to treat certain types of cancer (including breast cancer, non-small cell lung cancer, ovarian cancer, pancreatic cancer, bladder cancer, bone cancer, Ewing’s sarcoma, mesenchymal chondrosarcoma osteosarcoma, dedifferentiated chondrosarcoma, head and neck cancers-cancer of the nasopharynx, hepatobiliary cancers including gallbladder cancer, Hodgkin lymphoma, kidney cancer, malignant pleural mesothelioma, non Hodgkin lymphoma, non-melanoma skin cancer – dermatofibrosarcoma protuberans (DFSP), occult primary, small cell lung cancer, soft tissue sarcoma, testicular cancer, thymic malignancies, uterine malignancies). It is a chemotherapy drug that works by slowing or stopping the growth of cancer cells. One commercial product of gemcitabine is Gemzar, which is supplied in a sterile form for intravenous use only.


[1] H. A. Burris, M. J. Moore, J. Andersen, M. R. Green, M. L. Rothenberg, M. R. Modiano, M. C. Cripps, R. K. Portenoy, A. M. Storniolo, P. Tarassoff, R. Nelson, F. A. Dorr, C. D. Stephens, D. D. Von Hoff (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial, 15, 2403-2413


Gemcitabine(Gemzar) belongs to the group of medicines called antimetabolites. It is used alone or in combination with other medicines to treat cancer of the breast, ovary, pancreas, and lung. Gemcitabine interferes with the growth of cancer cells, which a

General Description

The drug is available as the hydrochloride salt in 200- and1,000-mg lyophilized single-dose vials for IV use.Gemcitabine is used to treat bladder cancer, breast cancer,pancreatic cancer, and NSCLC. Gemcitabine is a potent radiosensitizer,and it increases the cytotoxicity of cisplatin.The mechanism of action of this fluorine-substituted deoxycytidineanalog involves inhibition of DNA synthesis andfunction via DNA chain termination. The triphosphatemetabolite is incorporated into DNA inhibiting severalDNA polymerases and incorporated into RNA inhibitingproper function of mRNA. Resistance can occur because ofdecreased expression of the activation enzyme deoxycytidinekinase or decreased drug transport as well as increasedexpression of catabolic enzymes. Drug oral bioavailabilityis low because of deamination within the GI tract, and thedrug does not cross the blood-brain barrier. Metabolism bydeamination to 2', 2'-difluorouridine (dFdU) is extensive.Drug toxicity includes myelosuppression, fever, malaise,chills, headache, myalgias, nausea, and vomiting.


Human systemic effects

Gemcitabine Preparation Products And Raw materials

Raw materials

Preparation Products

Gemcitabine Suppliers

Global( 325)Suppliers
Supplier Tel Fax Email Country ProdList Advantage
Lianyungang happen teng technology co., LTD
15950718863 CHINA 305 58
Frapp's ChemicalNFTZ Co., Ltd.
+86 (576) 8169-6106
+86 (576) 8169-6105 China 886 50
Capot Chemical Co.,Ltd.
+86 (0)571-855 867 18
+86 (0)571-858 647 95 China 19918 60
Shenzhen Sendi Biotechnology Co.Ltd.
0755-23311925 18102838259
0755-23311925 CHINA 3203 55
Henan DaKen Chemical CO.,LTD.
+86-371-55531817 CHINA 21954 58
Beijing Cooperate Pharmaceutical Co.,Ltd.
+86-10-60279497 +86(0)15646567669
+86-10-60279497 CHINA 1530 55
Henan Tianfu Chemical Co.,Ltd.
0371-55170693 CHINA 20680 55
Shanghai Time Chemicals CO., Ltd.
+86-021-57951555 CHINA 1367 55
Mainchem Co., Ltd.
+86-0592-6210733 CHINA 32457 55
Nanjing ChemLin Chemical Industry Co., Ltd.
025-83697070; CHINA 3015 60

View Lastest Price from Gemcitabine manufacturers

Image Release date Product Price Min. Order Purity Supply Ability Manufacturer
2018-12-19 Gemcitabine
US $1.00 / kg 1kg 95%-99% 100kg career henan chemical co

95058-81-4(Gemcitabine)Related Search:

  • 2'-Deoxy-2',2'-difluro cytidine Hydrochloride
  • 2'-Deoxy-2',2'-difluoro-D-cytidine
  • 2',2'-Difluorodeoxycytidine
  • Cytidine, 2'-deoxy-2',2'-difluoro-
  • gemicitabine
  • NSC 613327
  • gencitabine base
  • 2',2'-Difluorodeoxycytidine (Gemcitabine base)
  • LY-18011
  • 4-amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one (Gemcitabine base)
  • GeMcitabine T8
  • GeMcitabine API
  • 122111-11-9 D-erythro-pentofuranose
  • GeMictabine
  • dFdC, dFdCyd, LY-188011
  • GeMcitabin
  • 2'-Deoxy-2',2'-difluorocytidine, >=99%
  • Gemcitabine free base
  • 3-Deoxy-2,2-difluoro-D-ribofuranose-3,5-dibenzoate
  • Gecitabine base
  • Folfugem
  • Gamcitabine
  • Gemcel
  • GemLip
  • Zefei
  • -
  • Antineoplastic
  • Inhibitors
  • 1-(4-Amino-2-oxo-1H-pyrimidin-1-yl)-2-deoxy-2,2-difluoro-beta-D-ribofuranose
  • 2'-Deoxy-2',2'-difluro cytidine
  • 4-amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
  • 4-Amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
  • 95058-81-4
  • C9H11F2N3O4
  • API
  • Antineoplastic drug, difluorine nucleoside analog
Copyright 2017 © ChemicalBook. All rights reserved